Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)

Kazuhiro Yamamoto; Hideki Origasa; Yasushi Suzuki; Toshiaki Takahashi; Tsuyoshi Shinozaki; Tomoyuki Watanabe; Yasushi Sakata; Chisato Izumi; Kayano Taira; Masatsugu Hori; Y. Sakata; O. Yamaguchi; T. Mano; K. Kinugawa; T. Oki; Y. Oishi; K. Ishikawa; H. Ito; T. Kosaka; T. Izumi; T. Inomata; K. Fujii; T. Yoshikawa; K. Onishi; Y. Maejima; M. Isobe; T. Nakamura; T. Takahashi; Y. Yasumura; K. Nishigaki; Y. Ueda; K. Kashiwase; Y. Tomo-hiro; Y. Suzuki; J. Yoshida; J. Nariyama; S. Yuda; T. Kawagoe; M. Matsuzaki; M. Yano; T. Yamamoto; H. Tsutsui; H. Okamoto; D. Goto; T. Souma; Y. Kijima; N. Iwahashi; T. Ebina; K. Kimura; R. Nakamura; M. Okamoto; N. Yamasaki; S. Ishikawa; T. Kajiya; Y. Ikeda; S. Hoshida; K. Ishikawa; K. Kusano; Y. Nakagawa; C. Izumi; K. Yasumori; M. Nishino; H. Yamaguchi; T. Takahashi; N. Maruyama; H. Abe; Y. Yasuoka; K. Node; H. Morita; M. Uematsu; M. Fujita; T. Watanabe; S. Ono; Y. Saito; M. Horii; K. Taira; T. Shinozaki; H. Yamamoto; F. Tadehara; M. Kuwahara; N. Ohte; Y. Takeda; T. Watanabe; K. Yamamoto

doi:10.1016/j.jjcc.2013.10.014

Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)

Kazuhiro Yamamoto, Hideki Origasa, Yasushi Suzuki, Toshiaki Takahashi, Tsuyoshi Shinozaki, Tomoyuki Watanabe, Yasushi Sakata, Chisato Izumi, Kayano Taira, Masatsugu Hori, Y. Sakata, O. Yamaguchi, T. Mano, K. Kinugawa, T. Oki, Y. Oishi, K. Ishikawa, H. Ito, T. Kosaka, T. IzumiT. Inomata, K. Fujii, T. Yoshikawa, K. Onishi, Y. Maejima, M. Isobe, T. Nakamura, T. Takahashi, Y. Yasumura, K. Nishigaki, Y. Ueda, K. Kashiwase, Y. Tomo-hiro, Y. Suzuki, J. Yoshida, J. Nariyama, S. Yuda, T. Kawagoe, M. Matsuzaki, M. Yano, T. Yamamoto, H. Tsutsui, H. Okamoto, D. Goto, T. Souma, Y. Kijima, N. Iwahashi, T. Ebina, K. Kimura, R. Nakamura, M. Okamoto, N. Yamasaki, S. Ishikawa, T. Kajiya, Y. Ikeda, S. Hoshida, K. Ishikawa, K. Kusano, Y. Nakagawa, C. Izumi, K. Yasumori, M. Nishino, H. Yamaguchi, T. Takahashi, N. Maruyama, H. Abe, Y. Yasuoka, K. Node, H. Morita, M. Uematsu, M. Fujita, T. Watanabe, S. Ono, Y. Saito, M. Horii, K. Taira, T. Shinozaki, H. Yamamoto, F. Tadehara, M. Kuwahara, N. Ohte, Y. Takeda, T. Watanabe, K. Yamamoto

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Background: The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF). However, it is unclear whether any risk factors modulate the effects of the standard-dose carvedilol. Methods and results: Data from 245 patients with HFPEF in J-DHF were evaluated. Decreased body mass index, diabetes mellitus, and left atrial (LA) dilatation were independent risk factors for both of the primary outcomes (cardiovascular death and unplanned hospitalization for heart failure) and another major composite outcome (cardiovascular death and unplanned hospitalization for any cardiovascular causes) in multivariable analysis. In patients with LA diameter ≥ the median value (43.2 mm), standard-dose carvedilol was associated with unadjusted hazard ratio (HR) 0.263 [95% confidence interval (CI): 0.080-0.859] and covariate adjusted 0.264 (0.080-0.876) for the primary outcome. In those with LA diameter < 43.2 mm, unadjusted and adjusted HRs were 1.123 (0.501-2.514) and 1.067 (0.472-2.412). A p-value for interaction was 0.046 (unadjusted) and 0.058 (adjusted). The similar effects of LA diameter were observed regarding another major composite outcome. The other risk factors in univariate or multivariable analyses did not influence the response to the standard-dose carvedilol. Conclusions: The standard-dose carvedilol may exert greater reduction of the incidence of clinical outcomes in the patients with HFPEF and advanced rather than mild diastolic dysfunction.

Original language	English
Pages (from-to)	424-431
Number of pages	8
Journal	Journal of cardiology
Volume	63
Issue number	6
DOIs	https://doi.org/10.1016/j.jjcc.2013.10.014
Publication status	Published - 2014 Jun

Keywords

Diastole
Heart failure
Left atrium
β-Blocker

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jjcc.2013.10.014

Cite this

Yamamoto, K., Origasa, H., Suzuki, Y., Takahashi, T., Shinozaki, T., Watanabe, T., Sakata, Y., Izumi, C., Taira, K., Hori, M., Sakata, Y., Yamaguchi, O., Mano, T., Kinugawa, K., Oki, T., Oishi, Y., Ishikawa, K., Ito, H., Kosaka, T., ... Yamamoto, K. (2014). Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of cardiology, 63(6), 424-431. https://doi.org/10.1016/j.jjcc.2013.10.014

Yamamoto, K, Origasa, H, Suzuki, Y, Takahashi, T, Shinozaki, T, Watanabe, T, Sakata, Y, Izumi, C, Taira, K, Hori, M, Sakata, Y, Yamaguchi, O, Mano, T, Kinugawa, K, Oki, T, Oishi, Y, Ishikawa, K, Ito, H, Kosaka, T, Izumi, T, Inomata, T, Fujii, K, Yoshikawa, T, Onishi, K, Maejima, Y, Isobe, M, Nakamura, T, Takahashi, T, Yasumura, Y, Nishigaki, K, Ueda, Y, Kashiwase, K, Tomo-hiro, Y, Suzuki, Y, Yoshida, J, Nariyama, J, Yuda, S, Kawagoe, T, Matsuzaki, M, Yano, M, Yamamoto, T, Tsutsui, H, Okamoto, H, Goto, D, Souma, T, Kijima, Y, Iwahashi, N, Ebina, T, Kimura, K, Nakamura, R, Okamoto, M, Yamasaki, N, Ishikawa, S, Kajiya, T, Ikeda, Y, Hoshida, S, Ishikawa, K, Kusano, K, Nakagawa, Y, Izumi, C, Yasumori, K, Nishino, M, Yamaguchi, H, Takahashi, T, Maruyama, N, Abe, H, Yasuoka, Y, Node, K, Morita, H, Uematsu, M, Fujita, M, Watanabe, T, Ono, S, Saito, Y, Horii, M, Taira, K, Shinozaki, T, Yamamoto, H, Tadehara, F, Kuwahara, M, Ohte, N, Takeda, Y, Watanabe, T & Yamamoto, K 2014, 'Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)', Journal of cardiology, vol. 63, no. 6, pp. 424-431. https://doi.org/10.1016/j.jjcc.2013.10.014

@article{808e165c933148a6a7caa114b30f9c98,

title = "Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)",

abstract = "Background: The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF). However, it is unclear whether any risk factors modulate the effects of the standard-dose carvedilol. Methods and results: Data from 245 patients with HFPEF in J-DHF were evaluated. Decreased body mass index, diabetes mellitus, and left atrial (LA) dilatation were independent risk factors for both of the primary outcomes (cardiovascular death and unplanned hospitalization for heart failure) and another major composite outcome (cardiovascular death and unplanned hospitalization for any cardiovascular causes) in multivariable analysis. In patients with LA diameter ≥ the median value (43.2 mm), standard-dose carvedilol was associated with unadjusted hazard ratio (HR) 0.263 [95% confidence interval (CI): 0.080-0.859] and covariate adjusted 0.264 (0.080-0.876) for the primary outcome. In those with LA diameter < 43.2 mm, unadjusted and adjusted HRs were 1.123 (0.501-2.514) and 1.067 (0.472-2.412). A p-value for interaction was 0.046 (unadjusted) and 0.058 (adjusted). The similar effects of LA diameter were observed regarding another major composite outcome. The other risk factors in univariate or multivariable analyses did not influence the response to the standard-dose carvedilol. Conclusions: The standard-dose carvedilol may exert greater reduction of the incidence of clinical outcomes in the patients with HFPEF and advanced rather than mild diastolic dysfunction.",

keywords = "Diastole, Heart failure, Left atrium, β-Blocker",

author = "Kazuhiro Yamamoto and Hideki Origasa and Yasushi Suzuki and Toshiaki Takahashi and Tsuyoshi Shinozaki and Tomoyuki Watanabe and Yasushi Sakata and Chisato Izumi and Kayano Taira and Masatsugu Hori and Y. Sakata and O. Yamaguchi and T. Mano and K. Kinugawa and T. Oki and Y. Oishi and K. Ishikawa and H. Ito and T. Kosaka and T. Izumi and T. Inomata and K. Fujii and T. Yoshikawa and K. Onishi and Y. Maejima and M. Isobe and T. Nakamura and T. Takahashi and Y. Yasumura and K. Nishigaki and Y. Ueda and K. Kashiwase and Y. Tomo-hiro and Y. Suzuki and J. Yoshida and J. Nariyama and S. Yuda and T. Kawagoe and M. Matsuzaki and M. Yano and T. Yamamoto and H. Tsutsui and H. Okamoto and D. Goto and T. Souma and Y. Kijima and N. Iwahashi and T. Ebina and K. Kimura and R. Nakamura and M. Okamoto and N. Yamasaki and S. Ishikawa and T. Kajiya and Y. Ikeda and S. Hoshida and K. Ishikawa and K. Kusano and Y. Nakagawa and C. Izumi and K. Yasumori and M. Nishino and H. Yamaguchi and T. Takahashi and N. Maruyama and H. Abe and Y. Yasuoka and K. Node and H. Morita and M. Uematsu and M. Fujita and T. Watanabe and S. Ono and Y. Saito and M. Horii and K. Taira and T. Shinozaki and H. Yamamoto and F. Tadehara and M. Kuwahara and N. Ohte and Y. Takeda and T. Watanabe and K. Yamamoto",

note = "Funding Information: This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan, and the Japan Heart Foundation . The authors gratefully acknowledge the support by Japan Clinical Research Assist Center in data management, Ms Marie Kusaka in secretarial assistance, and the Japanese Circulation Society. ",

year = "2014",

month = jun,

doi = "10.1016/j.jjcc.2013.10.014",

language = "English",

volume = "63",

pages = "424--431",

journal = "Journal of Cardiology",

issn = "0914-5087",

publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",

number = "6",

}

TY - JOUR

T1 - Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)

AU - Yamamoto, Kazuhiro

AU - Origasa, Hideki

AU - Suzuki, Yasushi

AU - Takahashi, Toshiaki

AU - Shinozaki, Tsuyoshi

AU - Watanabe, Tomoyuki

AU - Sakata, Yasushi

AU - Izumi, Chisato

AU - Taira, Kayano

AU - Hori, Masatsugu

AU - Sakata, Y.

AU - Yamaguchi, O.

AU - Mano, T.

AU - Kinugawa, K.

AU - Oki, T.

AU - Oishi, Y.

AU - Ishikawa, K.

AU - Ito, H.

AU - Kosaka, T.

AU - Izumi, T.

AU - Inomata, T.

AU - Fujii, K.

AU - Yoshikawa, T.

AU - Onishi, K.

AU - Maejima, Y.

AU - Isobe, M.

AU - Nakamura, T.

AU - Takahashi, T.

AU - Yasumura, Y.

AU - Nishigaki, K.

AU - Ueda, Y.

AU - Kashiwase, K.

AU - Tomo-hiro, Y.

AU - Suzuki, Y.

AU - Yoshida, J.

AU - Nariyama, J.

AU - Yuda, S.

AU - Kawagoe, T.

AU - Matsuzaki, M.

AU - Yano, M.

AU - Yamamoto, T.

AU - Tsutsui, H.

AU - Okamoto, H.

AU - Goto, D.

AU - Souma, T.

AU - Kijima, Y.

AU - Iwahashi, N.

AU - Ebina, T.

AU - Kimura, K.

AU - Nakamura, R.

AU - Okamoto, M.

AU - Yamasaki, N.

AU - Ishikawa, S.

AU - Kajiya, T.

AU - Ikeda, Y.

AU - Hoshida, S.

AU - Ishikawa, K.

AU - Kusano, K.

AU - Nakagawa, Y.

AU - Izumi, C.

AU - Yasumori, K.

AU - Nishino, M.

AU - Yamaguchi, H.

AU - Takahashi, T.

AU - Maruyama, N.

AU - Abe, H.

AU - Yasuoka, Y.

AU - Node, K.

AU - Morita, H.

AU - Uematsu, M.

AU - Fujita, M.

AU - Watanabe, T.

AU - Ono, S.

AU - Saito, Y.

AU - Horii, M.

AU - Taira, K.

AU - Shinozaki, T.

AU - Yamamoto, H.

AU - Tadehara, F.

AU - Kuwahara, M.

AU - Ohte, N.

AU - Takeda, Y.

AU - Watanabe, T.

AU - Yamamoto, K.

N1 - Funding Information: This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan, and the Japan Heart Foundation . The authors gratefully acknowledge the support by Japan Clinical Research Assist Center in data management, Ms Marie Kusaka in secretarial assistance, and the Japanese Circulation Society.

PY - 2014/6

Y1 - 2014/6

N2 - Background: The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF). However, it is unclear whether any risk factors modulate the effects of the standard-dose carvedilol. Methods and results: Data from 245 patients with HFPEF in J-DHF were evaluated. Decreased body mass index, diabetes mellitus, and left atrial (LA) dilatation were independent risk factors for both of the primary outcomes (cardiovascular death and unplanned hospitalization for heart failure) and another major composite outcome (cardiovascular death and unplanned hospitalization for any cardiovascular causes) in multivariable analysis. In patients with LA diameter ≥ the median value (43.2 mm), standard-dose carvedilol was associated with unadjusted hazard ratio (HR) 0.263 [95% confidence interval (CI): 0.080-0.859] and covariate adjusted 0.264 (0.080-0.876) for the primary outcome. In those with LA diameter < 43.2 mm, unadjusted and adjusted HRs were 1.123 (0.501-2.514) and 1.067 (0.472-2.412). A p-value for interaction was 0.046 (unadjusted) and 0.058 (adjusted). The similar effects of LA diameter were observed regarding another major composite outcome. The other risk factors in univariate or multivariable analyses did not influence the response to the standard-dose carvedilol. Conclusions: The standard-dose carvedilol may exert greater reduction of the incidence of clinical outcomes in the patients with HFPEF and advanced rather than mild diastolic dysfunction.

AB - Background: The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF). However, it is unclear whether any risk factors modulate the effects of the standard-dose carvedilol. Methods and results: Data from 245 patients with HFPEF in J-DHF were evaluated. Decreased body mass index, diabetes mellitus, and left atrial (LA) dilatation were independent risk factors for both of the primary outcomes (cardiovascular death and unplanned hospitalization for heart failure) and another major composite outcome (cardiovascular death and unplanned hospitalization for any cardiovascular causes) in multivariable analysis. In patients with LA diameter ≥ the median value (43.2 mm), standard-dose carvedilol was associated with unadjusted hazard ratio (HR) 0.263 [95% confidence interval (CI): 0.080-0.859] and covariate adjusted 0.264 (0.080-0.876) for the primary outcome. In those with LA diameter < 43.2 mm, unadjusted and adjusted HRs were 1.123 (0.501-2.514) and 1.067 (0.472-2.412). A p-value for interaction was 0.046 (unadjusted) and 0.058 (adjusted). The similar effects of LA diameter were observed regarding another major composite outcome. The other risk factors in univariate or multivariable analyses did not influence the response to the standard-dose carvedilol. Conclusions: The standard-dose carvedilol may exert greater reduction of the incidence of clinical outcomes in the patients with HFPEF and advanced rather than mild diastolic dysfunction.

KW - Diastole

KW - Heart failure

KW - Left atrium

KW - β-Blocker

UR - http://www.scopus.com/inward/record.url?scp=84902199357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902199357&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2013.10.014

DO - 10.1016/j.jjcc.2013.10.014

M3 - Article

C2 - 24286855

AN - SCOPUS:84902199357

SN - 0914-5087

VL - 63

SP - 424

EP - 431

JO - Journal of Cardiology

JF - Journal of Cardiology

IS - 6

ER -

Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - A report from the Japanese Diastolic Heart Failure Study (J-DHF)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this